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Hypersynchronicity of neuronal brain circuits is a feature of Alzheimer’s disease (AD). Mouse models of AD
expressing mutated forms of the amyloid-β precursor protein (APP), a central protein involved in AD pathology,
show cortical hypersynchronicity. We studied hippocampal circuitry in APP23 transgenic mice using telemetric
electroencephalography (EEG), at the age of onset of memory deficits. APP23 mice display spontaneous
hypersynchronicity in the hippocampus including epileptiform spike trains. Furthermore, spectral contributions
of hippocampal theta and gamma oscillations are compromised in APP23 mice, compared to non-transgenic
controls. Using cross-frequency coupling analysis, we show that hippocampal gamma amplitude modulation
by theta phase is markedly impaired in APP23 mice. Hippocampal hypersynchronicity and waveforms are
differentially modulated by injection of riluzole and the non-competitive N-methyl-D-aspartate (NMDA) receptor
inhibitor MK801, suggesting specific involvement of voltage-gated sodium channels and NMDA receptors in
hypersynchronicity thresholds in APP23 mice. Furthermore, APP23 mice show marked activation of p38
mitogen-activated protein (MAP) kinase in hippocampus, and injection of MK801 but not riluzole reduces activation
of p38 in the hippocampus. A p38 inhibitor induces hypersynchronicity in APP23 mice to a similar extent as MK801,
thus supporting suppression of hypersynchronicity involves NMDA receptors-mediated p38 activity. In summary, we
characterize components of hippocampal hypersynchronicity, waveform patterns and cross-frequency coupling in the
APP23 mouse model by pharmacological modulation, furthering the understanding of epileptiform brain activity in AD.
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Alzheimer’s disease (AD) is characterized by cognitive
decline, and presents histopathologically with amyloid-β
(Aβ) deposition in extracellular plaques and intracellular
neurofibrillary tangles made up of hyperphosphorylated
tau [1,2]. Besides these pathological hallmarks, it is be-
coming increasingly clear that AD is associated with al-
terations in neuronal circuit excitability. Patients with
Alzheimer’s disease have an increased risk of developing* Correspondence: l.ittner@unsw.edu.au
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epileptiform activity [3,4]. AD is associated with a 5- to
10-fold increase in seizure incidence, and seizure inci-
dence correlates with lower cognitive performance [4].
Although seizures were previously thought to be second-
ary to disease progression, aberrant neuronal activity
may directly contribute to cognitive deficits, as neuronal
activity appears to regulate regional vulnerability to Aβ
[5]. Modulating epileptiform hippocampal activity mod-
ulates cognitive deficits in patients with mild cognitive
impairment [6]. Conversely, forms of epilepsy are ac-
companied by cognitive impairments [7,8]. Thus, epilep-
tiform activity may contribute to the development oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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epileptiform activity in AD is incompletely understood.
Synchronous network oscillations contribute to nor-
mal brain activity, yet, are affected by epileptogenesis
[9,10]. In the hippocampus, two main oscillations reflect
physiological synchronous activities, both being impli-
cated in behavioural states and memory performance:
theta oscillations (4-12 Hz), generated by synchronous
phasic firing of pyramidal cells [11,12], and gamma os-
cillations (25-100 Hz), generated by circuits between
GABAergic interneurons and pyramidal cells [13].
GABAergic interneurons play a key role in synchronization
of pyramidal cell firing by providing rhythmic inhibition of
pyramidal cells [14]. In addition, hippocampal interneurons
are themselves synchronized by recurrent excitation [13].
Neuronal networks show further levels of interconnectivity:
the phase of theta rhythms modulates the amplitude of
gamma oscillations in the hippocampus, and this phase-
amplitude cross-frequency coupling (CFC) is critical in
hippocampus-dependent memory and cognitive perform-
ance [15-20]. Whether epileptiform activity in AD corre-
lates with aberrations in CFC between hippocampal theta
and gamma oscillations is not known. However, aberrant
generation of electroencephalographic oscillations has been
observed in cognitive impairment and AD [21], and aber-
rant hippocampal oscillations have been suggested to occur
early in development of AD [22].
Neuronal expression of human amyloid-β precursor
protein (APP) carrying pathogenic mutations has been
used to model AD in mice [23]. APP transgenic mice
exhibit extensive aberrant neuronal network and epilepti-
form activity [24-32]. Modulating hyperactivity and seizure
susceptibility in the hippocampus modulates cognitive def-
icits in APP transgenic mice [27,31,33,34]. Hippocampal
gamma spectral power, a measure of the contribution of
gamma frequencies to the entire signal strength, is mark-
edly diminished in 8 month-old behaving J20 mice ex-
pressing mutated hAPP [35]. Cross-frequency coupling
between theta phase and fast gamma amplitude is altered
in hippocampal slice cultures from APP transgenic mice
[36]. However, a concise analysis of hypersynchronicity,
spectral and CFC aberrations in adult APP mice in vivo is
lacking. Furthermore, the pathways that contribute to
network aberrations and hypersynchronicity in APP mice
remain incompletely understood.
Oligomeric Aβ may itself affect neuronal circuit exci-
tation [24]. Aβ reduces excitatory neuronal transmission
and plasticity at the synaptic level [37-41]. Neuronal
hyperexcitation and concomitant excitotoxicity in APP
transgenic mice require the microtubule associated
protein tau [2,33,42]. Dysfunction of synaptic NMDA re-
ceptors and their downstream signals was shown to
underlie loss of inhibitory currents and abnormal hyper-
excitation in hippocampal preparations from APP mice[31]. However, what contributions synaptic NMDA recep-
tors and inhibitory neuron function have in generation
and propagation of neuronal network aberrations and
hypersynchronicity remains unclear. Furthermore, signal-
ling pathways that may modulate thresholds for aberrant
network activity are incompletely understood. Recently,
mitogen-activated protein (MAP) kinase p38 has been
implicated in the Aβ-induced inhibition of long-term po-
tentiation (LTP) in brain slice cultures [43]. The role of
p38 activity in neuronal network alterations of APP trans-
genic mice, however, has not been investigated.
In this study, we examined hippocampal hypersynchro-
nicity in adult APP23 transgenic mice using in vivo tele-
metric electroencephalography (EEG) in free-roaming
mice and analyse interictal recording sequences for spec-
tral amplitude distribution and CFC strength before the
onset of plaque pathology. We report spontaneous hippo-
campal hypersynchronicity in APP23 transgenic mice
accompanied by marked spectral changes and impaired
CFC for theta and gamma oscillations. Furthermore, we
addressed thresholds of hypersynchronicity and interictal
spectral and CFC distributions upon pharmacological
manipulations of voltage-gated sodium channels, which
regulate GABAergic inhibition, by riluzole and of NMDA
receptors, by the non-competitive inhibitor MK801. Fur-
thermore, we found that MK801 treatment significantly
reduces activation of p38 MAP kinase in the hippocam-
pus, and inhibition of p38 alters hippocampal hypersyn-
chronicity thresholds in APP23 mice.
Materials and methods
Mice
APP23 transgenic mice on C57BL6 background were
described previously [44]. All animal experiments were
approved by the Animal Ethics Committee of the Univer-
sity of New South Wales. Mice were housed in 12 hour/
12 hour light dark cycle with food ad libitum. Mice used
in this study (electroencephalography and histology: 5
APP23 transgenic and 5 non-transgenic littermates; im-
munoblots: 3-4 mice per experimental group) were
4 month-old males.
EEG implantation
Wire EEG electrodes on remote telemetric transmitters
(DSI) were implanted as previously described [45].
Briefly, after anesthesia with ketamine/xylazine, scalp in-
cision along the midline was performed. The head was
fixed in a stereotactic frame (Kopf instruments) and the
bregma was located. Bone openings were drilled using a
bone micro-drill (Fine Science Tools, F.S.T.) at positions
previously described for the hippocampus (x 2.0, y -2.0,
z -2 with reference to bregma). Electrodes were inserted
at this position with reference electrode placed above
the cerebellum (x 0, y -6.0, z 0 from bregma). Electrodes
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closure and rehydration. Correct placement of electrodes
was confirmed by serial sections of paraffin embedded
brain tissue with hematoxylin-eosin staining. Only re-
cordings from mice with proper placement of electrodes
were included in further analysis. Two days after all EEG
recordings were performed, animals were sacrificed by
transcardial perfusion with cold phosphate-buffered sa-
line (PBS) and brain samples were extracted for further
processing for histological analysis.EEG data recording
Electroencephalograms were recorded with a DSI wire-
less receiver setup (DSI) with amplifier matrices using
the Dataquest A.R.T. recording software at 500 Hz sam-
pling rate [45]. Recordings were screened manually for
movement artefacts and only artefact-free EEG passages
were used in analysis. Raw LFP were noise filtered using
a powerline noise filter (Neuroscore, DSI).EEG data analysis
Analysis of EEG recordings was performed using the
NeuroScore software v3.0 (DSI) with integrated spike
detection module. Spike trains were thus detected auto-
matically and statistical data on spike train duration, fre-
quency and number of spikes per train were obtained.
Spectral analysis (i.e. analysis of signal power at individ-
ual frequencies expressed as square of the fast Fourier
transform (FFT) magnitude) of intra-ictal sequences was
performed using the integrated FFT spectral analysis
function of NeuroScore. Frequency bands of theta and
gamma wave forms were defined between 4-12 Hz and
25-100 Hz, respectively. Gamma and theta spectral con-
tributions were quantified by area-under-curve (AUC)
analysis across the defined frequency band in 3 artefact-
and hypersynchronous spike-free sequences per record-
ing (each 1 min in length). Cross-frequency coupling of
theta phase and gamma amplitude was performed using
MATLAB as previously described [20]. Briefly, for cross
frequency coupling analysis, raw LFP was noise filtered
using a powerline noise filter (Neuroscore, DSI). Noise-
filtered LFP was filtered at two frequency ranges of
interest for gamma (fA) and theta (fp). The phase time
series for theta (Φfp(t)) and the amplitude envelope time
series for gamma (AfA(t)) were obtained by Hilbert trans-
formation of the filtered LFPs. The combined series [Φfp
(t), AfA(t)] was then generated. After phase binning, the
means Ā fA(j) of AfA for each bin j were calculated and
normalized using the sum
XN
j¼1
Af A jð Þ of Ā fA(j) over N
bins to generate phase-amplitude distribution P(j). The
modulation index is based on calculating the Kullback-
Leibler distance DKL between the non-uniform (i.e.coupled) phase-amplitude distribution P(j) over all phase
bins and the uniform (i.e. uncoupled) distribution U(j).






The modulation index MI is defined as
MI ¼ DKL P jð Þ;U jð Þð Þ
log Nð Þ
Phase-amplitude distributions and modulation indices
were determined from artefact- and hypersynchronous
spike-free 3 sequences (each 1 min) per recording before
and after treatment.
Antibodies
The following antibodies were used: phospho-p38 (Cell
Signaling Technologies), p38 (Santa Cruz), APP (22C11),
APP (6E10), glyceraldehydephosphate dehydrogenase
(GAPDH) (all Millipore).
Immunofluorescence
Immunostainings were performed as previously described
[46]. Briefly, brain hemispheres from PBS-perfused mice
were fixed with 4% paraformaldehyde in PBS at 4 degrees
for 4 hours. Fixed brain samples were processed for paraffin
embedding in a histoprocessor (Excelsior Tissue Processor,
Thermo Shandon). Paraffin-embedded brain samples were
sectioned (5 μm) on a microtome (Leica). After de-
paraffinization, rehydration and washing, samples were
incubated with blocking buffer (5%BSA, 1% horse serum,
PBS pH7.4) and subsequently incubated with primary
antibody overnight. Slides were washed and incubated with
secondary antibody coupled to Alexa (Molecular probes)
fluorophores in blocking buffer. After washing, samples
were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) and mounted with Fluoromount (Sigma-Aldrich,
St. Louis, MO, USA) mounting medium.
Western blotting
Brain tissue was extracted from mice immediately after
cervical dislocation and brain hemispheres were dis-
sected to isolate the hippocampus. Hippocampal isolates
were homogenized immediately in RIPA buffer (50 mM
Tris, pH 8, 150 mM NaCl, 1% Nonidet P-40, 5 mM
EDTA, 0.5% sodium deoxycholate, 0.1% sodium dodecyl-
sulfate (SDS), 0.02 mM NaF, 1 mM phenylmethylsulfo-
nyl fluoride, 1 mM NaVO4 and protease inhibitors
(Complete, Roche Applied Science)) by passing through
a 29G syringe, incubated on ice for 20 min and centri-
fuged for 10 min at 12,000 × g and 4°C. Protein concen-
trations were determined by Bradford assay (BioRad).
Western blotting was performed as previously described
[47]. Equal amounts of protein samples were denatured
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HCl pH6.8, 2% SDS, 0.02% Bromophenol Blue, 1%
β-mercaptoethanol) at 95°C for 5 minutes. Protein sam-
ples and molecular weight standards were loaded on 10%
SDS-polyacrylamide gels and separated by electrophoresis.
Proteins were transferred onto nitrocellulose membrane
(Millipore) in transfer buffer (25 mM Tris, 192 mM gly-
cine, 20% methanol, 0.1% SDS). Membranes were washed
with TBST (10 mM Tris pH7.4, 150 mM NaCl, Tween-20
0.05%), blocked with 5% bovine serum albumin (Sigma-
Aldrich) in TBST and probed with primary antibodies
diluted in 5% bovine serum albumin (Sigma-Aldrich) in
TBST overnight at 4°C or for 1 hour at room temperature.
Primary antibodies used were: anti-p38 (Santa Cruz; 1:400),
anti-phospho-p38 (Threonine180/Tyrosine182; Cell Signal-
ing; 1:1000), anti-human APP (22C11; Chemicon; 1:1000),
anti-GAPDH (Chemicon; 1:5000). After three washes
with TBST, membranes were incubated with secondary
antibody-HRP conjugate diluted in 5% bovine serum
albumin (Sigma-Aldrich) in TBST. Secondary antibody
horseradish peroxidase (HRP)-conjugates used were:
goat-anti-rabbit conjugate (Santa Cruz, 1:5000), goat-
anti-mouse conjugate (Santa Cruz, 1:5000). After three
washes with TBST, HRP-catalysed enhanced chemolu-
minescence (ECL) reaction was visualized on a digital
imager (ChemiDoc, BioRad).
Statistics
Statistical analysis was performed using Graphpad Prizm.
T-test was used for comparison of two sets of normally
distributed data; ANOVA was used for comparison of
more than 2 data sets.
Results
Spontaneous hippocampal spikes and spike trains in
APP23 transgenic mice
To record hippocampal oscillations in APP23 transgenic
mice, we implanted focal telemetric EEG electrodes into
the hippocampus of male transgenic mice and non-
transgenic littermates. APP23 mice at the age of study
(4 months) showed prominent expression of APP and
Aβ detected by the monoclonal antibody 6E10 in hippo-
campus and neocortex, however, in the absence of an
overt amyloid plaque pathology (Figure 1A). Ten days
after surgeries, EEG was recorded alongside activity for
24 hours. Frist, we analysed EEG traces from APP23
transgenic and non-transgenic mice for seizure spike
trains, consisting of high-frequency polyspike or repeti-
tive sharp wave structures. We found spontaneous spike
trains in APP23 transgenic mice (Figure 1B,C and D;
spike trains per 24 h: n = 5, t = 3.054, p = 0.0185 (non-trans-
genic vs APP23), Student t-test; spikes per spike train:
n = 5, t = 2.221, p = 0.0346 (non-transgenic vs APP23), Stu-
dent t-test; spike train duration: n = 5, t = 2.446, p = 0.0210(non-transgenic vs APP23), Student t-test). Occurrence of
spike trains did not correlate with increased locomotive ac-
tivity, indicative of silent epileptiform episodes (Figure 1B).
Hippocampal EEG recordings from non-transgenic litter-
mates did not show spike activity (Figure 1E). Thus, APP23
transgenic mice display spontaneous epileptiform activity
detectable by EEG.Altered spectral power of theta and gamma oscillations
in APP23 mice
Hippocampal theta (4-12 Hz) and gamma rhythms
(25-100 Hz) are implicated in behavioural states and
memory performance [11-13]. Theta and gamma rhythms
have previously not been characterized in APP23 EEG
recordings. To address the contribution of theta and
gamma oscillations to the total power of recorded po-
tentials, we performed spectral power analysis of interic-
tal EEG recordings. APP23 mice showed markedly lower
power of high frequency theta oscillations (~10 Hz) as
compared with non-transgenic mice during the active
phase of the light cycle (Figure 2A,B,C and E; n = 5
animals 6-8 measurements each, t = 7.029, p < 0.0001,
Student’s t-test). In contrast, the spectral power of low
frequency gamma oscillations (25-50 Hz) was markedly
higher in APP23 mice as compared with non-transgenic
controls (Figure 2A,B,D and F; n = 5 animals 6-8 mea-
surements each, t = 2.569, p = 0.0116, Student’s t-test).
Thus, APP23 transgenic mice present with inverse alter-
ations in spectral power of hippocampal theta and gamma
oscillations.Impaired hippocampal CFC in APP23 mice
Hippocampal gamma and theta oscillations show marked
CFC that is considered central to hippocampal cognitive
functions such as spatial awareness and memory represen-
tation [16,48]. We addressed CFC in in vivo recordings
from adult APP23 transgenic mice, which has not been
done in APP expressing mice in vivo thus far. On noise-
filtered interictal recordings, APP23 mice showed mark-
edly fewer events of CFC coinciding with peaks of the
gamma amplitude envelope and the theta phase, as com-
pared with non-transgenic mice (Figure 3A). To address
phase-amplitude coupling across theta (4-12 Hz) and
gamma (25-100 Hz) frequencies, we used a comodulo-
gram plot that simultaneously reports the level of coupling
among multiple bands on the basis of scanning frequency
band pairs [20]. Comodulogram plots of non-transgenic
mice show several frequency pairs with significant
coupling, in particular at ~6 Hz (Figure 3B). In con-
trast, APP23 comodulogram plots showed markedly lower
coupling intensities across theta frequencies (Figure 3B). To
quantify CFC in relation to theta phase, we plotted





Figure 1 Spontaneous hippocampal hypersynchronicity and spike trains in EEG of adult APP23 mice. (A) Representative images of
immunofluorescence stainings on hippocampal sections from non-transgenic (non-tg) and APP23 mice (4 months) for APP/Aβ (6E10). DAPI,
4′,6-diamidino-2-phenylindole. Scale bars, 100 μm (B) APP23 transgenic hippocampal EEG during active phase of day-night cycle. EEG trace
(local field potential, LFP) (upper panel) and activity trace (lower panel) showing spontaneous spike activity and spike train (marked up with
dashed line). Representative recording from 5 animals is shown. (C) Magnification of EEG trace in B showing representative spike train in
hippocampal recording from APP23 transgenic mouse. (D) Spike train quantifications for APP23 and non-transgenic (non-tg) recordings over 24 hours.
(n = 5) Values are mean ± s.e.m.; ND, none detected (E) Hippocampal EEG from non-transgenic mouse during active phase of day-night cycle. EEG trace
and magnification of EEG trace (marked up with dashed line) are shown. Representative recording from 5 animals is shown.
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controls during the active phase of the light cycle
(Figure 3C). Non-transgenic phase-amplitude distribu-
tions peak in synchrony with theta phase – indicative
of significant CFC (Figure 3C). However, phase-
amplitude distributions in APP23 recordings did not show
a significant peak during the theta phase (Figure 3C).
The modulation index (MI) was described as a robust
statistics of CFC [20]. APP23 recordings used to calcu-
late phase-amplitude distributions had a significantly
lower modulation index compared to recordings from
non-transgenic mice (Figure 3D; n = 5 animals 2-3
measurements each, t = 2.456, p = 0.0239, Student’s t-test).
Taken together, our CFC analyses show that APP23 have
significantly weaker modulation of gamma amplitude by
the theta phase.Riluzole-induced acute hippocampal hypersynchronicity
in APP23 mice
Riluzole injection was shown to induce cortical hyper-
synchronicity in APP transgenic J20 mice [34]. However,
the effects of riluzole on EEG in other APP transgenic
mice as well as on additional EEG parameters (i.e. theta
oscillations and CFC) remained to be shown. To test
whether riluzole induces hippocampal hypersynchroni-
city in APP23 mice, we injected transgenic mice and
non-transgenic controls intraperitoneally with riluzole
and recorded hippocampal EEG before and after admin-
istration. In non-transgenic mice, riluzole induced a pro-
gressive and persisting reduction of oscillation amplitude
and frequency (Figure 4A). In contrast, APP23 mice
started showing increased and prolonged hypersyn-




Figure 2 Reduced theta and increased gamma spectral power in APP23 mice. (A) Raw hippocampal EEG (LFP) and band pass filtered
signals for theta (4-12 Hz) and gamma (25-100 Hz) oscillations in APP23 and non-transgenic (non-tg) mice. Representative signals from 5 animals
per genotype are shown. (B) Spectral power of EEG waves in APP23 transgenic mice and non-transgenic (non-tg) controls during active phase.
Dashed boxes mark theta (4-12 Hz) and gamma (25-100 Hz) oscillations. (n = 5) means ± s.e.m. (C) Magnified spectrum of theta oscillations. (n = 5)
means ± s.e.m. (D) Magnified spectrum of gamma oscillations. (n = 5) means ± s.e.m. (E) Quantification of spectral power contribution of theta
oscillations. (n = 5) means ± s.e.m. ***p < 0.001 (Student’s t-test) (F) Quantification of spectral power contribution of gamma oscillations. (n = 5)
means ± s.e.m. *p < 0.05 (Student’s t-test).
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throughout the recording period (Figure 4B,C and D;
spike trains per 120 min: n = 5, t = 3.639, p = 0.0066
(non-transgenic vs APP23), Student t-test; spikes per
spike train: n = 5, t = 2.884, p = 0.0063 (non-transgenic
vs APP23), Student t-test; spike train duration: n = 5,
t = 3.426, p = 0.0014 (non-transgenic vs APP23), Student
t-test). Riluzole-induced spike trains in APP23 mice where
interspersed by single spike events (Figure 4C). No spikes
were detected in riluzole-treated non-transgenic mice.
Riluzole had different effects on spectral periodograms re-
corded in non-transgenic and APP23 mice (Figure 4A,B).
To quantify effects on spectral power of theta and gamma
frequency bands, power spectra were averaged from
recordings at 20 minutes after injection with riluzole
and before treatment. At baseline, APP23 transgenic
mice showed consistently and significantly weaker
high-frequency theta waves (in particular those peaking
at 10 Hz) compared to non-transgenic (Figure 4E,F;
n = 5 animals 8-12 measurements each, F3,181 = 66.77,
p < 0.0001, ANOVA). Upon injection with riluzole, theta
power was markedly reduced in non-transgenic animals,
however, significantly enhanced in APP23 transgenic mice,
in particular at low frequencies (≤4 Hz) (Figure 4E,F).
Power of gamma oscillations was higher in APP23 spectra
compared to non-transgenic control recordings before
riluzole injection (Figure 4G,H; n = 5 animals 8-12measurements each, F3,181 = 7.141, p = 0.0001, ANOVA).
While non-transgenic mice showed significantly suppressed
gamma oscillations upon riluzole injection, APP23
spectra showed a significant relative increase of gamma
oscillation power after injection with riluzole (Figure 4G, H).
Riluzole had no significant effect on theta-gamma CFC in
non-transgenic mice as indicated by similar modulation
index values (Figure 4I; n = 5 animals 2-3 measurements
each, F3,38 = 6.014, p = 0.0019, ANOVA). In contrast,
APP23 recordings showed marked CFC impairment be-
fore riluzole injection, and a surprising increase in
coupling strength was measured after riluzole injection
(Figure 4I). Thus, marked modulation of oscillations at
gamma and theta frequencies and an enhanced CFC
strength are concomitant with increased hypersynchroni-
city upon injection with riluzole in APP23 mice compared
to non-transgenic controls.
Non-competitive NMDA receptor inhibition enhanced
spike activity in APP23 transgenic mice
Direct inhibition of NMDA receptors may affect hyper-
synchronicity in APP23 mice. Therefore, we treated
APP23 mice and non-transgenic controls with the non-
competitive NMDA receptor inhibitor MK801, and re-
corded hippocampal EEGs before and after injection.
Upon MK801 injection, non-transgenic mice showed no
indication of hypersynchronicity (Figure 5A,C and D). In
AB
C D
Figure 3 Gamma amplitude modulation by theta phase is impaired in APP23 mice. (A) Raw EEG (LFP), band pass filtered signals for theta
(4-12 Hz) and gamma (25-100 Hz) oscillations, gamma amplitude envelope (green) and theta phase in APP23 and non-transgenic (non-tg) mice.
Representative signals from 5 animals per genotype are shown. (B) Representative phase-amplitude comodulograms computed for hippocampal
LFPs recorded in non-transgenic (non-tg) and APP23 mice. (C) Phase-amplitude plot computed for hippocampal LFPs recorded in non-transgenic
(non-tg) and APP23 mice. (n = 5) means ± s.e.m. (D) Modulation index computed for the phase-amplitude distributions shown in C. (n = 5) means ±
s.e.m. *p < 0.05 (Student’s t-test).
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rence of hypersynchronicity in APP23 mice (Figure 5B,
C and D; spike trains per 120 min: n = 5, t = 2.360, p =
0.0244 (non-transgenic vs APP23), Student t-test; spikes
per spike train: n = 5, t = 2.364, p = 0.0244 (non-transgenic
vs APP23), Student t-test; spike train duration: n = 5,
t = 2.499, p = 0.0176 (non-transgenic vs APP23), Student
t-test). Periodograms showMK801 treatment-induced power
and frequency shifts in theta frequencies (Figure 5A and B).
In-depth spectral analysis revealed that, similar to non-
transgenic recordings, MK801 induced strong increases in
power of theta oscillations in APP23 spectra (Figure 5E,F;
n = 5 animals 8-12 measurements each, F3,186 = 67.80,
p < 0.0001, ANOVA). Power of gamma oscillations was
suppressed to similar extents by MK801 in APP23 andnon-transgenic mice (Figure 5G,H; n = 5 animals 8-12
measurements each, F3,186 = 20.70, p < 0.0001, ANOVA).
However, strength of gamma oscillations remained still
higher in APP23 spectra compared with non-transgenic
spectra after MK801 injections (Figure 5G,H). Calculation
of the ratio of spectral power pre and post injection of
MK801 in non-transgenic and APP23 recordings showed
that MK801 had a significant effect on theta power ratio
in APP23 mice (Figure 5I n = 5 animals 8-12 measure-
ments each, t = 2.750, p = 0.0175, Student’s t-test), yet did
not affect gamma power ratios (Figure 5J n = 5 animals
8-12 measurements each, t = 0.3210, p = 0.7491, Student’s
t-test), suggesting a pronounced involvement of MK801-
induced theta power changes correlating with MK801-
induced hypersynchronicity. CFC impairments in APP23
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coupling strength was not affected by MK801 (Figure 5K;
n = 5 animals 2-3 measurements each, F3,23 = 5.768, p =
0.0043, ANOVA). Taken together, while MK801 treatment
enhances the power of theta waveforms in hippocampal
EEG in APP23 and in non-transgenic mice, it does not
affect CFC strength. However, MK801 induces hippocam-
pal hypersynchronicity in APP23, suggesting that the
threshold to hypersynchronicity in transgenic mice is gov-
erned by NMDA receptors.
MK801 inhibits p38 MAP kinase activity in the APP23
hippocampus
Pathways downstream of NMDA receptors in hippocam-
pal neurons have been implicated in neurotoxicity,
hypersynchronicity and pathology in AD mouse models
including the APP23 transgenic mice [2,49]. Down-
stream events include calcium influx and activation of
kinase signalling [49,50]. Aβ has been shown to regulate
p38 MAPK downstream of NR2B-containing NMDA re-
ceptors [43]. Here, we investigated the effect of riluzole
and MK801 on p38 activation (i.e. phosphorylated p38)
in the hippocampus of APP23 mice using Western blot-
ting. While riluzole did not significantly alter the levels
of p38 phosphorylation, APP23 mice injected with
MK801 showed markedly lower hippocampal p38 phos-
phorylation (Figure 6A,B). p38 activation has been
reported at very early stages in AD [51] and in APP
transgenic mice [52]. Accordingly, we found higher hip-
pocampal levels of active p38 in APP23 mice compared
to non-transgenic controls (Figure 6C). Furthermore,
hippocampal phospho-p38 levels were sensitive to sys-
temic application of p38 inhibitor SB203580 (Figure 6C).
Thus, increased p38 activation in APP23 could be re-
duced by blocking NMDA receptors.
p38 inhibition enhances hippocampal hypersynchronicity
in APP23 mice
The NMDA receptor-dependence of p38 phosphoryl-
ation in APP23 mice prompted us to investigate the
effects of the p38 inhibitor SB203580 on hippocampal
EEG. SB203580 treatment did not induce hypersynchro-
nicity in non-transgenic mice (Figure 6D,F and G), yet
significantly enhanced hypersynchronicity in APP23 trans-
genic (Figure 6E,F and G; spike trains per 120 min: n = 5,
t = 3.534, p = 0.0095 (non-transgenic vs APP23), Student
t-test; spikes per spike train: n = 5, t = 3.063, p = 0.0032
(non-transgenic vs APP23), Student t-test; spike train
duration: n = 5, t = 3.194, p = 0.0021 (non-transgenic vs
APP23), Student t-test). Furthermore, SB203580-injected
APP23 transgenic mice showed recurring individual spikes
beginning at approximately 60 minutes post-injection
(Figure 6F), followed by series of short spike trains
(Figure 6E,G). SB203580 treatment resulted in a frequencyshift of theta oscillations towards slow waveforms
(peaking around 4 Hz) in both APP23 transgenic and
non-transgenic mice non-transgenic mice (Figure 6H).
However, quantitation of spectra over the entire theta band
(4-12 Hz) showed no significant difference in non-
transgenic mice before and after SB203580 treatment, yet an
increase of overall power of theta oscillations in APP23 mice
with SB203580 treatment (Figure 6I; n = 5 animals 8-14
measurements each, F3,220 = 12.28, p < 0.0001, ANOVA).
SB203580 treatment led to significant decrease in gamma
wave power in both APP23 and non-transgenic mice
(Figure 6J,K; n = 5 animals 8-14 measurements each,
F3,220 = 22.37, p < 0.0001, ANOVA). Similar to MK801
(Figure 5I), SB203580 treatment did not impact on
interictal CFC strength in APP23 and non-transgenic
mice (Figure 6L; n = 5 animals 3-4 measurements
each, F3,54 = 7.212, p = 0.0004, ANOVA). Taken to-
gether, administration of the p38 inhibitor SB203580
induced enhanced hippocampal hypersynchronicity in
APP23 mice, while modulating theta oscillations and
suppressing gamma oscillations in APP23 and non-
transgenic control mice.Discussion
In the present study, we report spontaneous hypersyn-
chronicity in APP23 transgenic mice. Furthermore, we
show that APP23 mice have marked alterations in theta
and gamma oscillations and impaired cross-frequency
gamma modulation by the phase of theta oscillations.
We found markedly enhanced spike activity in APP23
after riluzole treatment. Surprisingly, we found that
hypersynchronicity in APP23 mice could be enhanced
by MK801 and the p38 inhibitor SB203580. Spectral
analysis showed that enhanced hypersynchronicity in
APP23 by riluzole, MK801 and SB203580 is accompan-
ied by alterations in theta and gamma wave power. CFC
analysis showed that impaired coupling strength in
APP23 mice, while not altered by MK801 or SB203580
treatment, is significantly increased by riluzole (Table 1).
Spontaneous hypersynchronicity, possible induced by
Aβ [53], has previously been described for transgenic
mouse models of AD [24-32,54]. Our study corroborates
previous findings by showing spontaneous hypersyn-
chronicity in APP23 mice, which express human
APP carrying the Swedish double mutation. APP23
mice present memory deficits as early as 3 months
of age [55], while plaque pathology is not seen be-
fore 6 months of age [44]. Our data show pro-
nounced neuronal network aberrations and EEG
abnormalities such as epileptiform activity, spectral
power differences and CFC impairments in APP23
mice already at an age when memory deficits mani-




Figure 4 Riluzole aggravates hippocampal hypersynchronicity in APP23 mice. Representative EEG trace (LFP) and periodogram (0-60 Hz) of
(A) non-transgenic and (B) APP23 transgenic mice, before and after administration of riluzole (20 mg/kg i.p.). (C) magnification of EEG traces
marked in A an B by dashed boxes. (n = 5). (D) Spike train quantification for APP23 and non-transgenic (non-tg) recordings after injection with
riluzole. (n = 5) Means ± s.e.m.; ND, none detected (E) Spectral power analysis of APP23 and non-transgenic (non-tg) recordings before and 20
minutes after injection of riluzole. Dashed box marks theta band. Means ± s.e.m. (n = 5). (F) Quantification of spectra in E. AUC, area under curve.
Means ± s.e.m. ****p < 0.001, ***p < 0.005 (ANOVA) (G) Spectral power analysis of APP23 and non-transgenic (non-tg) recordings before and 20
minutes after injection of riluzole. Dashed box marks gamma band. Means ± s.e.m. (n = 5). (H) Quantification of spectra in G. AUC, area under
curve. Means ± s.e.m. **p < 0.01 *p < 0.05 (ANOVA) (I) Modulation index before and 20 minutes after injection with riluzole. (n = 5) means ± s.e.m.
**p < 0.01 *p < 0.05 ns, not significant (ANOVA).
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campal p38 activation. Neuronal networks may even
be compromised before memory deficits develop,since network aberrations and hypersynchronicity
have been observed in brain slices of APP-expressing







Figure 5 (See legend on next page.)
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Figure 5 NMDA receptor inhibition enhances hippocampal spike activity in APP23 mice. Representative EEG trace (LFP) and periodogram
(0-60 Hz) of (A) non-transgenic and (B) APP23 transgenic mice before and after injection of MK801 (0.4 mg/kg i.p.). (C) magnification of EEG traces
marked in A an B by dashed box. (n = 5) (D) Spike train statistics for APP23 and non-transgenic (non-tg) recordings after injection of MK801. (n = 5)
Mean ± s.e.m.; ND, none detected (E) Spectral power analysis of APP23 and non-transgenic (non-tg) recordings before and 20 minutes after injection
of MK801. Dashed box marks theta band. Means ± s.e.m. (n = 5). (F) Quantification of spectra in E. AUC, area under curve. Means ± s.e.m. ****p < 0.001
***p < 0.005 **p < 0.01 *p < 0.05 (ANOVA) (G) Spectral power of EEG waves in APP23 transgenic mice and non-transgenic (non-tg) controls before and
20 minutes after injection of MK801. Dashed box marks gamma band. Means ± s.e.m. (n = 5). (H) Quantification of spectra in G. AUC, area under curve.
Means ± s.e.m. **p < 0.01 (ANOVA) (I) Ratio of theta power pre/post-injection of MK801. (n = 5) means ± s.e.m. * p < 0.05 (Student’s t-test) (J) Ratio of
gamma power pre/post-injection of MK801. (n = 5) means ± s.e.m. not significant (Student’s t-test) (K) Modulation index before and 20 minutes after
injection of MK801. (n = 5) means ± s.e.m. **p < 0.01 *p < 0.05 ns, not significant (ANOVA).
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theta power in APP23 EEG recordings, while strength of
gamma oscillations was significantly increased (Figure 2).
As outlined above, hippocampal oscillations of theta and
gamma frequencies contribute to physiological processes
required in memory and cognition [11-13]. Thus, hippo-
campal network aberrations leading to spectral changes
in these frequency bands may underlie onset of cognitive
deficits in APP23 mice [55,56]. Alternative APP-expressing
mouse models show similar alterations in theta and gamma
waveforms [34,36,54]. Consistent with these findings in
murine models, early human AD pathology and mild
cognitive impairment is accompanied by alterations in
neuronal network oscillations [21,22,24]. Whether altered
spectral power of theta oscillations also influence thresholds
for epileptiform activity in AD remains unclear. However,
data from rodent models of epilepsy suggest that a slow os-
cillation state affects hypersynchronicity thresholds [57].
Thus, spectral power changes in theta oscillations may
affect hypersynchronicity in APP23 mice.
Hippocampal gamma oscillations are generated by cir-
cuits between GABAergic interneurons and pyramidal
cells [13,35]. Interestingly, our interictal hippocampal re-
cordings show increased gamma oscillations in APP23
mice compared to recordings from non-transgenic mice
(Figure 2). These findings suggest altered network top-
ology in APP23 limbic systems, which potentially include
aberrant circuit activity of GABAergic interneurons and
pyramidal cells. In human epilepsy and rodent models of
epilepsy, pre-seizure states are characterized by enhanced
gamma oscillations [58]. However, these findings may not
be directly translatable to epileptogenesis in APP trans-
genic mice. APP-expressing mice have been reported with
changes in distribution and survival of GABAergic inter-
neurons at early stages [59-61]. Cortical hypersynchroni-
city in APP mice and its relation to gamma oscillations
and function of GABAergic interneurons has recently
been investigated in detail [34]. Verret et al. elegantly
showed that cortical gamma oscillations are impaired dur-
ing strong hypersynchronicity in mutant APP transgenic
J20 mice, compared to pre-ictal sequences within the same
recordings. Different from this previous study, we focused
on analysis of recording sequences that were notcharacterized by hypersynchronicity and made compari-
sons between APP23 and non-transgenic mice rather than
of pre-ictal and ictal states. Thus, we do not conclude on
gamma oscillations during hypersynchronicity states in
the hippocampus of APP23 mice. Nevertheless, the study
by Verret et al., our study and findings by others [36,54]
indicate that altered network oscillations are an inherent
phenotype of APP transgenic mice.
To our knowledge, our study represents the first re-
port of hippocampal CFC deficits in adult APP trans-
genic mice. Previously, slice recordings have been
analysed for theta phase to gamma amplitude coupling,
however, only very young mice were used [36]. Intri-
guingly, CFC and spectral changes were present before
high levels of Aβ were detectable in these mice [36].
These findings and our data suggest that CFC deficits
occur early and persist over time in APP transgenic
mice. They may thus contribute to hypersynchronicity
and behavioural/memory deficits in APP transgenic
mouse models that are already seen at this age. However,
until now there are no mechanistic implications of CFC
changes in epileptiform activity. So our study provides
the first correlation of CFC deficits and hypersynchro-
nous activity in the brains of APP-expressing mice. The
above-mentioned study by Goutagny et al also describes
alterations in spectral contributions from theta and
gamma oscillations in slices of APP transgenic TgCRND8
mice [36], similar to what we detected in APP23 EEG
recordings. CFC calculation measures used in our study
(i.e. comodulogram plots, phase-amplitude distribution
and modulation index) are based on normalized gamma
amplitudes [20]. Therefore, these measures allow for quan-
titative coupling strength comparison between APP23 and
non-transgenic recordings.
Riluzole blocks persistent sodium currents by inhibit-
ing voltage-gated sodium channels [62]. In vivo, riluzole
has anticonvulsive and sedative effects in rodents and
humans [63,64]. We found that riluzole injection in
APP23 mice leads to strong induction of hypersynchro-
nicity, an increase in theta oscillation power, yet a shift
towards lower theta frequencies. It also enhanced the
power of gamma oscillations. A synchronized hippocam-
pal slow oscillation state lowers the threshold for








Figure 6 (See legend on next page.)
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Figure 6 The p38 inhibitor SB203580 enhances hippocampal spike activity in APP23 mice. (A) Immunoblot using hippocampal lysates
from APP23 transgenic or non-transgenic (non-tg) mice injected with riluzole (RIL), MK801 (MK) or vehicle control (VEH) probed for human APP,
phospho-p38, p38 and GAPDH. Representative blot with 3 mice per group is shown. (B) Quantification of immunoblots (n = 3-4) means ± s.d.
**p < 0.01 (ANOVA) (C) Immunoblot of hippocampal lysates from APP23 transgenic mice or non-transgenic (non-tg) injected with SB203580
(SB, 0.4 mg/kg i.p.) or vehicle control (VEH) probed for human APP, phospho-p38, p38 and GAPDH. Representative blot with 3 mice per group is
shown. (D, E) Representative EEG trace (LFP) and periodogram (0-60 Hz) of (D) non-transgenic and (E) APP23 transgenic mice before and after
injection of SB203580 (0.4 mg/kg i.p.). (F) Magnified EEG traces marked in D and E by dashed box. (n = 5). (G) Spike train quantification. (n = 5)
Means ± s.e.m.; ND, none detected (H) Spectral power analysis of APP23 and non-transgenic (non-tg) recordings before and 60 minutes after
injection of SB203580. Dashed box marks theta band. Means ± s.e.m. (n = 5). (I) Quantification of spectra in H. AUC, area under curve. Means ±
s.e.m. **p < 0.01 ns, not significant (ANOVA) (J) Spectral power of EEG waves in APP23 transgenic mice and non-transgenic (non-tg) controls
before and 60 minutes after injection of SB203580. Dashed box marks gamma band. Means ± s.e.m. (n = 5). (K) Quantification of spectra in J.
AUC, area under curve. Means ± s.e.m. ***p < 0.005 **p < 0.01 *p < 0.05 (ANOVA) (L) Modulation index before and 60 minutes after injection of
SB203580. (n = 5) means ± s.e.m. **p < 0.01 *p < 0.05 ns, not significant (ANOVA).
Ittner et al. Acta Neuropathologica Communications 2014, 2:149 Page 13 of 17
http://www.actaneurocomms.org/content/2/1/149propagation and generation of epileptiform activity [57].
We found that riluzole causes frequency shift towards
slow oscillations (≤4 Hz) in interictal EEG sequences,
thus potentially instigating a slow oscillation state that
lowers hypersynchronicity thresholds. This is neither
seen with MK801 nor with SB203580, where interictal
recordings still show a significant component of theta
(4-12 Hz) in APP23 mice and induced hypersynchroni-
city was less pronounced (Table 1). Thus, the oscillatory
state of hippocampal slow waves may be deterministic of
seizure thresholds in APP transgenic mice.
Riluzole has been shown to enhance hypersynchro-
nous states in cortical recordings from APP-expressing
J20 mice [34]. Interestingly, riluzole suppressed gamma
oscillations in cortical recordings from J20 mice [34],
which is consistent with its effect on hippocampal
gamma oscillations in APP23 mice in our study. We ex-
tended our analysis of riluzole-induced changes in EEG
parameter to CFC between theta and gamma oscilla-
tions. Surprisingly, CFC strength was markedly increased
in APP23 mice after riluzole injection, even though these
mice show CFC impairment before injection. Even
though non-transgenic mice show reductions in theta




Spike trains per 2 hours (n/120 min) 11.6 ± 3.2
Spikes/spike train 69.4 ± 3.9
Spike train duration (s) 12.38 ± 2.09
Theta power ↓ ↑
Theta frequency ↓ ↓
Gamma power ↓ ↑
Cross-frequency coupling → ↑
p38 MAPK activity nt →
↑, increase; ↓, decrease; →, unchanged; ND, not detectable; nt, not tested. Values arCFC in non-transgenic mice are insignificant, suggesting
that riluzole has unique effects in APP-expressing mice
that might impact directly or indirectly on generation
and/or propagation of hypersynchronous activity. Our
data are the first to correlate an increase in CFC strength
with enhanced hypersynchronicity in EEG recordings in
mice. The close correlation of riluzole-induced interictal
surge in CFC strength and increased epileptiform activity
in APP23 mice may imply a causal connection on a net-
work level. Thus, our data using the APP23 mouse model
tentatively imply that CFC analysis algorithms may prove
useful to predict epileptiform episode in recordings of AD
patients.
Voltage-gated sodium channels, targeted by riluzole,
show altered expression and processing in mouse models
of AD, which correlates with aberrant EEG activity and
memory impairments, as well as altered sensitivity to rilu-
zole [34,60]. The contribution of riluzole-sensitive sodium
channels in cortical interneurons has been suggested to
underlie the hypersynchronous effect of riluzole on cor-
tical neuron networks [34]. This may to some extent
translate to the hippocampal network in APP23 mice, as
function of hippocampal GABAergic interneurons is im-
paired in epilepsy [14]. In the rodent hippocampus,P23 and non-transgenic controls
MK801 SB203580
non-tg APP23 non-tg APP23
ND ↑ ND ↑
6.0 ± 1.2 8.3 ± 2.7
40.9 ± 7.0 12.4 ± 1.1
6.97 ± 0.74 4.24 ± 0.35
↑ ↑ → →
→ → ↓ →
↓ ↓ ↓ ↓
→ → → →
nt ↓ ↓ ↓
e means ± s.e.m.
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to interneurons, but also occurs in pyramidal CA neurons
[65,66]. Thus, inhibition of voltage-gated sodium channels
may have broad impact on neuronal networks in the
hippocampus and – as secondary effect – may cause sup-
pression of glutamate release [63,67]. How, such broad
sodium channel inhibition contributes mechanistically to
hippocampal hypersynchronicity remains unclear. Inter-
estingly, riluzole had opposite effects on theta and gamma
spectral power in our recordings from non-transgenic and
APP23 mice. This suggests that riluzole induces a specific
interictal state in APP mice that combines increased low
frequency theta, enhanced gamma oscillations and a pro-
nounced gamma-theta coupling that might lower network
thresholds for epileptogenesis. Given the direct mode of
action of riluzole is inhibition of voltage-gated sodium
channels, the dissimilarity of EEG responses of non-
transgenic and APP23 mice is likely due to differences in
expression of these channels as shown for other APP-
expressing mice [34].
Next, we used MK801, a non-competitive activity-
dependent inhibitor of NMDA receptors, to address
effects of NMDA receptor inhibition on hypersynchro-
nicity and other EEG parameters in APP23 mice.
Surprisingly, MK801 induced significant epileptiform
activity in hippocampal recordings from APP23 mice,
albeit to a lower extent as seen after administration of
riluzole. Interestingly and different from the effects of rilu-
zole, MK801 injection resulted in strongly enhanced theta
oscillation and suppressed gamma oscillations, whilst not
leading to frequency shifts (Table 1). MK801 also had sig-
nificant effects of on theta and gamma spectral power in
non-transgenic recordings. Therefore, we calculated the
ratios of spectral power pre- and post-injection with
MK801, which showed that theta, but not gamma, spectral
power was significantly affected in APP23 mice. Further-
more, MK801 injection did not affect CFC strength. Thus,
we argue that MK801 instigates a markedly different oscil-
latory state – in particular of theta rhythms - than riluzole
in the hippocampus of APP23 mice, though both induce
forms of hypersynchronicity. This suggests that a compo-
nent in hypersynchronicity thresholds of APP23 mice is
governed by NMDA receptors. Furthermore, neuronal
populations may contribute differentially to hypersynchro-
nicity in APP23 mice. In epilepsy models, MK801 inhibits
epileptogenesis [68] or has no effects [69]. Therefore, the
APP-dependent network alterations leading to hypersyn-
chronicity may be unique to AD models with compro-
mised NMDA receptor function. Interestingly, stargazer
mice with a mutation in the Cacng2 gene that encodes
stargazin, a protein that regulates AMPA receptor traffick-
ing and excitability in interneurons, show increased seiz-
ure length and hyperexcitability upon NMDA receptor
inhibition by MK801 [70]. AMPA receptor trafficking maybe affected in APP transgenic mice. Consistent with this
idea, Aβ and expression of mutated APP have been shown
to reduce synaptic prevalence of AMPA receptors, thereby
affecting synapse function [40,71].
We found p38 MAP kinase activity to be increased in
APP23 mice. Interestingly, MK801, but not riluzole
treatment results in lowered p38 MAP kinase activation
in the hippocampus of APP23 mice (Figure 6A, Table 1).
Surprisingly, suppressing hippocampal p38 activity with
a pyridylimidazole-based inhibitor results in increased
hypersynchronicity. Hence, increased p38 activity in
APP23 hippocampus may be part of a protective mech-
anism limiting synchronized activity of neuronal circuits.
MK801 treatment of APP23 mice resulted in similarly
enhanced hypersynchronicity as after p38 inhibitor ad-
ministration. Even though p38 inhibition – despite ef-
fective in the hippocampus – may affect other brain
areas or organ systems (e.g. peripheral nervous system,
vascular system), the effects seen with MK801 or p38
inhibitor could be mechanistically linked within hippo-
campal neurons. In support of this, NMDA receptors
have been linked to p38 activation during promoting
neuronal death [43,49,72]. Interestingly, Aβ or mutated
APP expression increases activation of p38 [43,52]. Con-
sistent with this, p38 might govern hypersynchronicity
in APP mice downstream of MK801-sensitive NMDA
receptors and this pathway may constitute a protective
signal from epileptiform activity in this AD model. The
molecular details of p38 signalling in this context as well
as effects of long-term suppression of p38 activation on
network aberrations and epileptiform activity remain to
be investigated. Whether long-term inhibition of p38 is
achievable in mice without affecting normal brain or
peripheral function is, however, unclear, as longitudinal
inhibitor studies of these functions are not available at
present.
In summary, hippocampal EEG recordings in adult
4-month old APP23 mice show spontaneous hypersyn-
chronicity, alterations in theta and gamma oscillation
and impaired coupling of theta phase and gamma ampli-
tude. Although, we found no apparent plaque burden in
the 4 months-old APP23 mice analysed here, APP23
mice show memory deficits as early as 3 months of age
and increased Aβ levels, as shown by others and us be-
fore [42,44,55]. While we determined EEG alterations in
APP23 mice at a single age (4 months), other APP-
expressing strains show hypersynchronicity and network
aberrations at earlier and later stages, suggesting that
APP23 mice likely show similar changes at similar ages
[34,36,54]. Furthermore, differentially enhanced compo-
nents of hypersynchronicity in APP23 mice after treat-
ment with either riluzole, MK801 or SB203580, suggest
involvement of sodium channels, NMDA receptors and
p38 MAP kinase signalling in governing thresholds of
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effects of short-term treatments with riluzole, MK801 or
SB203580 on hippocampal EEG may well translate into
changes in behaviour and memory performance specific-
ally in APP23. Whether they are also reflected by
changes in distribution or survival of neuronal subtypes
(e.g. GABAergic interneurons) in the hippocampus of
APP23 mice remains to be determined.
Abbreviations
NMDA: N-methyl-D-aspartate; GABA: Gamma-aminobutyric acid; Hz: Hertz.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The authors like to thank Adriano Tort (Brain Institute, Federal University of
Rio Grande do Norte Natal, Brazil) for providing the Mathlab codes for CFC
analysis. Author contributions: A.I. designed and performed experiments,
analysed data, wrote manuscript; A.G., J.B. and L.S. performed experiments
and analysed data; L.M.I. designed study and experiments, wrote manuscript.
The research has been supported by funding from the National Health &
Medical Research Council (NHMRC), the Australian Research Council (ARC),
Alzheimer Association and the University of New South Wales. L.M.I. is an
NHMRC Senior Research Fellow.
Author details
1Dementia Research Unit, School of Medical Sciences, Faculty of Medicine,
UNSW Australia, Sydney, Australia. 2Neuroscience Research Australia (NeuRA),
Sydney, Australia. 3UNSW Australia, Kensington 2052NSW, Australia.
Received: 21 August 2014 Accepted: 8 October 2014
References
1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8
(2):101–112. doi: 10.1038/nrm2101
2. Ittner LM, Gotz J (2011) Amyloid-beta and tau–a toxic pas de deux in
Alzheimer's disease. Nat Rev Neurosci 12(2):65–72. doi:10.1038/nrn2967
3. Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR (2013) Seizures in
patients with Alzheimer's disease or vascular dementia: a population-based
nested case-control analysis. Epilepsia 54(4):700–707. doi:10.1111/epi.12045
4. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K,
Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures
in patients with Alzheimer's disease. Epilepsia 47(5):867–872. doi:10.1111/
j.1528-1167.2006.00554.x
5. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman
DM (2011) Neuronal activity regulates the regional vulnerability to amyloid-beta
deposition. Nat Neurosci 14(6):750–756. doi:10.1038/nn.2801
6. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA,
Bassett SS, Shelton AL, Gallagher M (2012) Reduction of hippocampal
hyperactivity improves cognition in amnestic mild cognitive impairment.
Neuron 74(3):467–474. doi:10.1016/j.neuron.2012.03.023
7. Chauviere L, Rafrafi N, Thinus-Blanc C, Bartolomei F, Esclapez M, Bernard C
(2009) Early deficits in spatial memory and theta rhythm in experimental
temporal lobe epilepsy. J Neurosci 29(17):5402–5410. doi:10.1523/JNEUR-
OSCI.4699-08.2009
8. Cornaggia CM, Beghi M, Provenzi M, Beghi E (2006) Correlation between
cognition and behavior in epilepsy. Epilepsia 47(Suppl 2):34–39. doi:10.1111/
j.1528-1167.2006.00685.x
9. Marcelin B, Chauviere L, Becker A, Migliore M, Esclapez M, Bernard C (2009)
h channel-dependent deficit of theta oscillation resonance and phase shift
in temporal lobe epilepsy. Neurobiol Dis 33(3):436–447. doi:10.1016/j.
nbd.2008.11.019
10. Traub RD, Pais I, Bibbig A, Lebeau FE, Buhl EH, Garner H, Monyer H,
Whittington MA (2005) Transient depression of excitatory synapses on
interneurons contributes to epileptiform bursts during gamma oscillationsin the mouse hippocampal slice. J Neurophysiol 94(2):1225–1235.
doi:10.1152/jn.00069.2005
11. Buzsaki G (2002) Theta oscillations in the hippocampus. Neuron 33(3):325–340
12. Colgin LL, Moser EI (2010) Gamma oscillations in the hippocampus.
Physiology 25(5):319–329. doi:10.1152/physiol.00021.2010
13. Mann EO, Radcliffe CA, Paulsen O (2005) Hippocampal gamma-frequency
oscillations: from interneurones to pyramidal cells, and back. J Physiol 562
(Pt 1):55–63. doi:10.1113/jphysiol.2004.078758
14. Cossart R, Dinocourt C, Hirsch JC, Merchan-Perez A, De Felipe J, Ben-Ari Y,
Esclapez M, Bernard C (2001) Dendritic but not somatic GABAergic inhibition is
decreased in experimental epilepsy. Nat Neurosci 4(1):52–62. doi:10.1038/82900
15. Jensen O, Colgin LL (2007) Cross-frequency coupling between neuronal
oscillations. Trends Cogn Sci 11(7):267–269. doi:10.1016/j.tics.2007.05.003
16. Tort AB, Komorowski RW, Manns JR, Kopell NJ, Eichenbaum H (2009) Theta-
gamma coupling increases during the learning of item-context associations.
Proc Natl Acad Sci U S A 106(49):20942–20947. doi:10.1073/pnas.0911331106
17. Canolty RT, Edwards E, Dalal SS, Soltani M, Nagarajan SS, Kirsch HE, Berger
MS, Barbaro NM, Knight RT (2006) High gamma power is phase-locked to
theta oscillations in human neocortex. Science 313(5793):1626–1628.
doi:10.1126/science.1128115
18. Axmacher N, Henseler MM, Jensen O, Weinreich I, Elger CE, Fell J (2010)
Cross-frequency coupling supports multi-item working memory in the
human hippocampus. Proc Natl Acad Sci U S A 107(7):3228–3233.
doi:10.1073/pnas.0911531107
19. Wulff P, Ponomarenko AA, Bartos M, Korotkova TM, Fuchs EC, Bahner F,
Both M, Tort AB, Kopell NJ, Wisden W, Monyer H (2009) Hippocampal theta
rhythm and its coupling with gamma oscillations require fast inhibition
onto parvalbumin-positive interneurons. Proc Natl Acad Sci U S A 106
(9):3561–3566. doi:10.1073/pnas.0813176106
20. Tort AB, Komorowski R, Eichenbaum H, Kopell N (2010) Measuring
phase-amplitude coupling between neuronal oscillations of different
frequencies. J Neurophysiol 104(2):1195–1210. doi:10.1152/jn.00106.2010
21. Grunwald M, Busse F, Hensel A, Kruggel F, Riedel-Heller S, Wolf H, Arendt T,
Gertz HJ (2001) Correlation between cortical theta activity and hippocampal
volumes in health, mild cognitive impairment, and mild dementia. J Clin
Neurophysiol 18(2):178–184
22. Goutagny R, Krantic S (2013) Hippocampal oscillatory activity in Alzheimer's
disease: toward the identification of early biomarkers? Aging and disease 4
(3):134–140
23. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and
frontotemporal dementia. Nat Rev Neurosci 9(7):532–544. doi:10.1038/nrn2420
24. Palop JJ, Mucke L (2009) Epilepsy and cognitive impairments in Alzheimer
disease. Arch Neurol 66(4):435–440. doi:10.1001/archneurol.2009.15
25. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S,
Eckman C, Younkin S, Price D, Iadecola C, Clark HB, Carlson G. (1995) Age-
related CNS disorder and early death in transgenic FVB/N mice overexpressing
Alzheimer amyloid precursor proteins. Neuron 15(5):1203–1218
26. Lalonde R, Dumont M, Staufenbiel M, Strazielle C (2005) Neurobehavioral
characterization of APP23 transgenic mice with the SHIRPA primary screen.
Behav Brain Res 157(1):91–98. doi:10.1016/j.bbr.2004.06.020
27. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO,
Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory
neuronal activity and compensatory remodeling of inhibitory hippocampal
circuits in mouse models of Alzheimer's disease. Neuron 55(5):697–711.
doi:10.1016/j.neuron.2007.07.025
28. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L,
Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H (2009) Amyloid
beta-induced neuronal hyperexcitability triggers progressive epilepsy.
J Neurosci 29(11):3453–3462. doi:10.1523/JNEUROSCI.5215-08.2009
29. Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, Pimplikar SW (2011)
Abnormal neuronal networks and seizure susceptibility in mice overexpressing
the APP intracellular domain. Neurobiol Aging 32(9):1725–1729. doi:10.1016/j.
neurobiolaging.2009.09.002
30. Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P,
Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L (2010) Transsynaptic progression
of amyloid-beta-induced neuronal dysfunction within the entorhinal-
hippocampal network. Neuron 68(3):428–441. doi:10.1016/j.
neuron.2010.10.020
31. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze
N, Yu GQ, Palop JJ, Noebels JL, Mucke L (2011) Amyloid-beta/Fyn-induced
synaptic, network, and cognitive impairments depend on tau levels in multiple
Ittner et al. Acta Neuropathologica Communications 2014, 2:149 Page 16 of 17
http://www.actaneurocomms.org/content/2/1/149mouse models of Alzheimer's disease. J Neurosci 31(2):700–711. doi:10.1523/
JNEUROSCI.4152-10.2011
32. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K,
Yu GQ, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal
network dysfunction and reverses synaptic and cognitive deficits in an
Alzheimer's disease model. Proc Natl Acad Sci U S A 109(42):E2895–2903.
doi:10.1073/pnas.1121081109
33. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H,
Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid
beta-induced deficits in an Alzheimer's disease mouse model. Science 316
(5825):750–754. doi:10.1126/science.1141736
34. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E,
Kreitzer AC, Mody I, Mucke L, Palop JJ (2012) Inhibitory interneuron deficit
links altered network activity and cognitive dysfunction in Alzheimer model.
Cell 149(3):708–721. doi:10.1016/j.cell.2012.02.046
35. Rubio SE, Vega-Flores G, Martinez A, Bosch C, Perez-Mediavilla A, del Rio J,
Gruart A, Delgado-Garcia JM, Soriano E, Pascual M (2012) Accelerated aging
of the GABAergic septohippocampal pathway and decreased hippocampal
rhythms in a mouse model of Alzheimer's disease. FASEB J 26(11):4458–4467.
doi:10.1096/fj.12-208413
36. Goutagny R, Gu N, Cavanagh C, Jackson J, Chabot JG, Quirion R, Krantic S,
Williams S (2013) Alterations in hippocampal network oscillations and
theta-gamma coupling arise before Abeta overproduction in a mouse
model of Alzheimer's disease. Eur J Neurosci 37(12):1896–1902.
doi:10.1111/ejn.12233
37. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D,
Malenka RC, Nicoll RA, Mucke L (1999) Plaque-independent disruption of
neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci
U S A 96(6):3228–3233
38. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ,
Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein
potently inhibit hippocampal long-term potentiation in vivo. Nature 416
(6880):535–539. doi:10.1038/416535a
39. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T,
Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron
37(6):925–937
40. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R (2006)
AMPAR removal underlies Abeta-induced synaptic depression and dendritic
spine loss. Neuron 52(5):831–843. doi:10.1016/j.neuron.2006.10.035
41. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL
(2007) Natural oligomers of the Alzheimer amyloid-beta protein induce
reversible synapse loss by modulating an NMDA-type glutamate
receptor-dependent signaling pathway. J Neurosci 27(11):2866–2875.
doi:10.1523/JNEUROSCI.4970-06.2007
42. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H,
Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E,
Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity
in Alzheimer's disease mouse models. Cell 142(3):387–397. doi:10.1016/j.
cell.2010.06.036
43. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011)
Soluble Abeta oligomers inhibit long-term potentiation through
a mechanism involving excessive activation of extrasynaptic NR2B-containing
NMDA receptors. J Neurosci 31(18):6627–6638. doi:10.1523/JNEUROSCI.0203-
11.2011
44. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C,
Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun
ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid
precursor protein transgenic mouse models with Alzheimer disease-like
pathology. Proc Natl Acad Sci U S A 94(24):13287–13292
45. Weiergraber M, Henry M, Hescheler J, Smyth N, Schneider T (2005)
Electrocorticographic and deep intracerebral EEG recording in mice using a
telemetry system. Brain Res Brain Res Protoc 14(3):154–164. doi:10.1016/j.
brainresprot.2004.12.006
46. Ittner AA, Bertz J, Chan TY, van Eersel J, Polly P, Ittner LM (2014) The
nucleotide exchange factor SIL1 is required for glucose-stimulated insulin
secretion from mouse pancreatic beta cells in vivo. Diabetologia.
doi:10.1007/s00125-014-3230-z
47. Ittner A, Block H, Reichel CA, Varjosalo M, Gehart H, Sumara G, Gstaiger M,
Krombach F, Zarbock A, Ricci R (2012) Regulation of PTEN activity by
p38delta-PKD1 signaling in neutrophils confers inflammatory responses in
the lung. J Exp Med 209(12):2229–2246. doi:10.1084/jem.2012067748. Newman EL, Gillet SN, Climer JR, Hasselmo ME (2013) Cholinergic blockade
reduces theta-gamma phase amplitude coupling and speed modulation of
theta frequency consistent with behavioral effects on encoding. J Neurosci
33(50):19635–19646. doi:10.1523/JNEUROSCI.2586-13.2013
49. Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA
receptor signalling: implications for neurodegenerative disorders. Nat Rev
Neurosci 11(10):682–696. doi:10.1038/nrn2911
50. Zheng S, Eacker SM, Hong SJ, Gronostajski RM, Dawson TM, Dawson VL
(2010) NMDA-induced neuronal survival is mediated through nuclear factor
I-A in mice. J Clin Invest 120(7):2446–2456. doi:10.1172/JCI33144
51. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN,
Stewart CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G (1999)
p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 72
(5):2053–2058
52. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW (2002) Activation of c-Jun
N-terminal kinase and p38 in an Alzheimer's disease model is associated with
amyloid deposition. J Neurosci 22(9):3376–3385. doi:20026352
53. Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in
Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13
(7):812–818. doi:10.1038/nn.2583
54. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler
DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL (2014) Genetic
suppression of transgenic APP rescues Hypersynchronous network activity
in a mouse model of Alzeimer's disease. J Neurosci 34(11):3826–3840.
doi:10.1523/JNEUROSCI.5171-13.2014
55. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De
Deyn PP (2003) Age-dependent cognitive decline in the APP23 model
precedes amyloid deposition. Eur J Neurosci 17(2):388–396
56. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E,
Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R,
Staufenbiel M, Sommer B (2003) Progressive age-related impairment of
cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24(2):365–378
57. Nazer F, Dickson CT (2009) Slow oscillation state facilitates epileptiform
events in the hippocampus. J Neurophysiol 102(3):1880–1889. doi:10.1152/
jn.90795.2008
58. Medvedev AV, Murro AM, Meador KJ (2011) Abnormal interictal gamma
activity may manifest a seizure onset zone in temporal lobe epilepsy. Int J
Neural Syst 21(2):103–114. doi:10.1142/S0129065711002699
59. Baglietto-Vargas D, Moreno-Gonzalez I, Sanchez-Varo R, Jimenez S,
Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Romero-Acebal M, Ruano
D, Vizuete M, Vitorica J, Gutierrez A (2010) Calretinin interneurons are
early targets of extracellular amyloid-beta pathology in PS1/AbetaPP
Alzheimer mice hippocampus. J Alzheimers Dis 21(1):119–132.
doi:10.3233/JAD-2010-100066
60. Corbett BF, Leiser SC, Ling HP, Nagy R, Breysse N, Zhang X, Hazra A, Brown
JT, Randall AD, Wood A, Pangalos MN, Reinhart PH, Chin J (2013) Sodium
channel cleavage is associated with aberrant neuronal activity and cognitive
deficits in a mouse model of Alzheimer's disease. J Neurosci 33(16):7020–7026.
doi:10.1523/JNEUROSCI.2325-12.2013
61. Takahashi H, Brasnjevic I, Rutten BP, Van Der Kolk N, Perl DP, Bouras C,
Steinbusch HW, Schmitz C, Hof PR, Dickstein DL (2010) Hippocampal
interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's
disease. Brain Struct Funct 214(2–3):145–160. doi:10.1007/s00429-010-0242-4
62. Urbani A, Belluzzi O (2000) Riluzole inhibits the persistent sodium current in
mammalian CNS neurons. Eur J Neurosci 12(10):3567–3574
63. Doble A (1996) The pharmacology and mechanism of action of riluzole.
Neurology 47(6 Suppl 4):S233–241
64. Saletu B, Grunberger J, Anderer P, Linzmayer L (1996) Effects of the novel
neuroprotective agent, riluzole, on human brain function and behavior: II.
Double-blind, placebo-controlled EEG mapping and psychometric studies
under hypoxia. Methods Find Exp Clin Pharmacol 18(1):67–81
65. Katoh-Semba R, Kaneko R, Kitajima S, Tsuzuki M, Ichisaka S, Hata Y, Yamada
H, Miyazaki N, Takahashi Y, Kato K (2009) Activation of p38 mitogen-
activated protein kinase is required for in vivo brain-derived neurotrophic
factor production in the rat hippocampus. Neuroscience 163(1):352–361.
doi:10.1016/j.neuroscience.2009.06.011
66. Park YY, Johnston D, Gray R (2013) Slowly inactivating component of Na+
current in peri-somatic region of hippocampal CA1 pyramidal neurons. J
Neurophysiol 109(5):1378–1390. doi:10.1152/jn.00435.2012
67. Azbill RD, Mu X, Springer JE (2000) Riluzole increases high-affinity glutamate
uptake in rat spinal cord synaptosomes. Brain Res 871(2):175–180
Ittner et al. Acta Neuropathologica Communications 2014, 2:149 Page 17 of 17
http://www.actaneurocomms.org/content/2/1/14968. Raza M, Blair RE, Sombati S, Carter DS, Deshpande LS, DeLorenzo RJ (2004)
Evidence that injury-induced changes in hippocampal neuronal calcium
dynamics during epileptogenesis cause acquired epilepsy. Proc Natl Acad
Sci U S A 101(50):17522–17527. doi:10.1073/pnas.0408155101
69. Loscher W (1998) Pharmacology of glutamate receptor antagonists in the
kindling model of epilepsy. Prog Neurobiol 54(6):721–741
70. Maheshwari A, Nahm WK, Noebels JL (2013) Paradoxical proepileptic
response to NMDA receptor blockade linked to cortical interneuron defect
in stargazer mice. Front Cell Neurosci 7:156. doi:10.3389/fncel.2013.00156
71. Gu Z, Liu W, Yan Z (2009) {beta}-Amyloid impairs AMPA receptor trafficking
and function by reducing Ca2+/calmodulin-dependent protein kinase II
synaptic distribution. J Biol Chem 284(16):10639–10649. doi:10.1074/jbc.
M806508200
72. Parsons MP, Raymond LA (2014) Extrasynaptic NMDA receptor involvement
in central nervous system disorders. Neuron 82(2):279–293. doi:10.1016/j.
neuron.2014.03.030
doi:10.1186/s40478-014-0149-z
Cite this article as: Ittner et al.: p38 MAP kinase-mediated NMDA
receptor-dependent suppression of hippocampal hypersynchronicity
in a mouse model of Alzheimer’s disease. Acta Neuropathologica
Communications 2014 2:149.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
